
Marwan Sabbagh
Vice Chair of Research · Barrow Neurological Institute at St Joseph's Hospital and Medical Center
Credentials: · · · · · ·
History
Present


- 1992–1995
- 1991–1992
Banner Good Samaritan Regional Medical Center
- 1983–1987
Research
Lecanemab in Early Alzheimer's Disease
New England Journal of Medicine · 2023 · 4,522 citations
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease
New England Journal of Medicine · 2014 · 1,518 citations
Use of florbetapir-PET for imaging beta-amyloid pathology
JAMA · 2011 · 888 citations
- TB
111 papers

83 papers

79 papers

61 papers
- CB
53 papers

45 papers · 6 as a resident
- SJ
37 papers

25 papers
Grants
- 2021–2028
Repurposing Siponimod for Alzheimer's Disease
National Institute on Aging · R01
Contact PI · $2.8M · St. Joseph's Hospital and Medical Center
- 2018–2025
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
National Institute on Aging · R01
Contact PI · $3.6M · St. Joseph's Hospital and Medical Center
- 2020–2024
Nevada Exploratory Alzheimer's Disease Research Center (NVEADRC)
National Institute on Aging · P20
Contact PI · $1.5M · Cleveland Clinic Foundation
- 2015–2021
Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - Resubmission
National Institute of General Medical Sciences · P20
Contact PI · $2.3M · Cleveland Clinic Foundation
Clinical trials
- 2025–2029
Repurposing Siponimod for Alzheimer's Disease
Principal investigator · Recruiting · Phase 2
St. Joseph's Hospital and Medical Center, Phoenix
- 2020–2025
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
Principal investigator · Completed · Phase 2
St. Joseph's Hospital and Medical Center, Phoenix
- 2016–2018
Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)
Principal investigator · Completed
St. Joseph's Hospital and Medical Center, Phoenix
- 2021–2022
Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks
Study director · Unknown · Phase 1, Phase 2
NeuroTau, Inc.



